Surrozen (SRZN) Long-Term Investments (2021 - 2022)
Surrozen (SRZN) posted quarterly Long-Term Investments of $11.8 million for Q1 2022, down 87.2% year-over-year from $92.0 million in Q1 2021, and down 45.6% quarter-over-quarter from $21.7 million in Q4 2021.
Surrozen (SRZN) Long-Term Investments (2021 - 2022) Analysis & Trends
Surrozen's Long-Term Investments history runs 2 years deep, the most recent figure standing at $11.8 million for Q1 2022.
- In Q1 2022, Long-Term Investments fell 87.2% year-over-year to $11.8 million; the TTM figure through Mar 2022 stood at $11.8 million (down 87.2% YoY), while the FY2021 annual figure was $21.7 million, changed N/A from the prior year.
- Long-Term Investments for Q1 2022 stood at $11.8 million, down from $21.7 million in the prior quarter.
- The five-year high for Long-Term Investments was $92.0 million in Q2 2021, with the low at $11.8 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 11.78 Mn |
| Dec 31, 2021 | 21.66 Mn |
| Sep 30, 2021 | 25.26 Mn |
| Jun 30, 2021 | 92.03 Mn |
| Mar 31, 2021 | 92.03 Mn |